MET and cancer: Of note, across treatment-naïve and -resistant cancers, upregulation of MET signaling occurs through an array of molecular events ranging from protein overexpression to genomic alterations, including amplification, mutations (e.g., exon 14 skipping), or chromosomal rearrangements25.